Avidity Biosciences

We are committed to building a diverse team with experience in rare disease and RNA therapies. Our team members bring an extensive array of expertise in research, development and commercial execution and we are focused on building a talented, diverse and collaborative team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining an inclusive workforce at all levels of the organization to ensure that different backgrounds and perspectives are being heard and integrated. Through our BeAVID values – Agile, Visionary, Integrated and Diverse – we consistently challenge ourselves to excel and deliver on our commitment to patients and their families.

We are delivering a new class of RNA therapeutics – Antibody Oligonucleotide Conjugates (AOCs™). AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Utilizing our proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD). We are broadening the reach of AOCs with our advancing and expanding pipeline including programs in precision cardiology and immunology through internal discovery efforts and key partnerships.

Avidity’s proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. We have three clinical development programs for three distinct rare muscle diseases. Delpacibart etedesiran abbreviated as del-desiran (AOC 1001), Avidity’s investigational lead product candidate utilizing its AOC platform is being studied in the Phase 3 global HARBOR™ trial in adults living with DM1. Del-desiran is also being studied in the ongoing MARINA-OLE™ trial with all of the participants who completed the Phase 1/2 MARINA® trial. Delpacibart braxlosiran abbreviated as del-brax (AOC 1020) is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. Avidity plans to accelerate initiation of registrational cohorts in the FORTITUDE study. Delpacibart zotadirsen abbreviated as del-zota (AOC 1044) is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. Del-zota is the first of multiple AOCs the company is developing for DMD.

Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Beyond our clinical programs for muscle diseases, we have expanded our research and development efforts to include additional tissues and cell types such as cardiac tissue and immune cells. We are driven to accelerate our research to tackle unmet needs and better serve patients and their families.